Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment.

ABSTRACT:

Introduction

Myasthenia gravis (MG) is a devastating acquired autoimmune disease that can seriously affect the patient's quality of life. It is also a common complication of thymoma. Previous studies have shown that docetaxel alleviates myasthenic symptoms in thymoma with MG (TMG). However, little is known about the protein expression profiles and biomarkers for efficacy after docetaxel treatment.

Methods

We recruited 9 healthy controls and 30 patients with TMG for the serum proteomics study with data-independent acquisition (DIA) technology. We further recruited additional 30 patients for the key protein validation by enzyme-linked immunosorbent assay (ELISA).

Results

We identified 43 proteins by trend analysis and analyzed the interaction between these proteins and

SUBMITTER: Yang H 

PROVIDER: S-EPMC10043105 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature